Overview
- AbbVie reported third‑quarter revenue of $17.40 billion and adjusted EPS of $3.82, beating analyst estimates and prompting the company to raise its 2026 adjusted profit forecast to $13.95–$13.99 per share following Friday’s report.
- The company said Skyrizi produced roughly $5.78 billion in sales and Rinvoq about $2.71 billion in the quarter, with those drugs now driving overall growth for the immunology franchise.
- Humira revenue fell sharply, down about 31.2% to $683 million for the quarter as competition eroded its former market position.
- AbbVie completed the $10.9 billion purchase of Apogee Therapeutics in June, which the company says will add eczema and asthma candidates to its pipeline but will weigh on profits through 2027 and is not expected to materially contribute to earnings until around 2032.
- Management announced a 5.2% dividend increase starting February 2027 and investors pushed the stock to a record high on the results, reflecting confidence in the new growth mix while signalling higher short‑term R&D and milestone costs for shareholders and patients awaiting new treatments.